9 news items
Market-Moving News for June 17th
BBY
QTTB
ZYME
17 Jun 24
BBY: 4% | UBS Upgrades Best Buy Co to Buy, Raises Price Target
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
ZYME
17 Jun 24
for ZW171, a novel 2+1 T-cell targeting bispecific antibody for mesothelin (MSLN)-expressing cancers. "We are excited to reach this R
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
ZYME
10 Jun 24
, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has also been recently accepted for Priority Review by the FDA with target action
Navigating 6 Analyst Ratings For Zymeworks
ZYME
6 Jun 24
0
0
Insights from analysts' 12-month price targets are revealed
HC Wainwright & Co. Reiterates Neutral on Zymeworks, Maintains $10 Price Target
ZYME
6 Jun 24
HC Wainwright & Co. analyst Robert Burns reiterates Zymeworks (NASDAQ:ZYME) with a Neutral and maintains $10 price target.
lcvyh59kh8ynyz2c7tiq3c
ZYME
11 Apr 24
and developed zanidatamab, a HER2-targeted bispecific antibody using the Company's proprietary Azymetric™ technology. Zymeworks has entered into separate
py2pcy4qthdv8b3assb1lzsuiqy8iphd34bry92lfmgispa6e4odo
ZYME
8 Apr 24
-drug conjugates and multispecific antibody therapeutics." Presentation Highlights ZW191 - a FRĪ±-targeting
5aff2vr75g3gnmxbx34i0hraum4v4w0pr663oayvmfwo
SNDX
ZYME
28 Mar 24
engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted
uu5lkday2 9vh
ZYME
27 Mar 24
in virtual one-on-one meetings and a panel discussion on April 15th at 3:00 pm ET.Stifel Virtual Targeted Oncology Days
- Prev
- 1
- Next